Transglutaminase inhibitors induce hyperproliferation and parakeratosis in tissue-engineered skin

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 247-257

  Harrison, C A ^a,b   Layton, C M ^b   Hau, Z ^a   Bullock, A J ^a   Johnson, T S ^a   MacNeil, S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Keratinocyte; Putrescine; Skin; Transglutaminase

Indexed keywords

COLLAGEN TYPE 4; CYTOKERATIN 10; CYTOKERATIN 16; CYTOKERATIN 6; ENZYME INHIBITOR; INVOLUCRIN; N BENZYLOXYCARBONYLGLUTAMINYL 6 DIMETHYLSULFONIUM 5 OXONORLEUCINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BASEMENT MEMBRANE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME INHIBITION; FIBROBLAST; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; PARAKERATOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TISSUE ENGINEERING;

CA-15-3 ANTIGEN; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; KERATINS; PARAKERATOSIS; PUTRESCINE; SKIN; TISSUE ENGINEERING; TRANSGLUTAMINASES;

EID: 33846206432     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07641.x     Document Type: Article

References (60)

1. Harrison CA, Gossiel F, Layton CM et al. Use of an in vitro model of tissue-engineered skin to investigate the mechanism of skin graft contraction. Tissue Eng 2006; (in press).
2. Chavanas S, Bodemer C, Rochat A et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25:141-2.
3. Raghunath M, Tontsidou L, Oji V et al. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol 2004; 123:474-83.
4. Huber M, Rettler I, Bernasconi K et al. Mutations of keratinocyte transglutaminase in lamellar ichthyosis. Science 1995; 267:525-8.
5. Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 1992; 27:40-50.
6. Rice RH, Crumrine D, Uchida Y et al. Structural changes in epidermal scale and appendages as indicators of defective TGM1 activity. Arch Dermatol Res 2005; 297:127-33.
7. Candi E, Oddi S, Paradisi A et al. Expression of transglutaminase 5 in normal and pathologic human epidermis. J Invest Dermatol 2002; 119:670-7.
8. Barsigian C, Stern AM, Martinez J. Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators. J Biol Chem 1991; 266:22501-9.
9. Aeschlimann D, Paulsson M. Cross-linking of laminin-nidogen complexes by tissue transglutaminase. A novel mechanism for basement membrane stabilization. J Biol Chem 1991; 266:15308-17.
10. Raghunath M, Hopfner B, Aeschlimann D et al. Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. Anchoring fibrils are a target for tissue transglutaminase. J Clin Invest 1996; 98:1174-84.
11. Aeschlimann D, Kaupp O, Paulsson M. Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate. J Cell Biol 1995; 129:881-92.
12. Aeschlimann D, Koeller MK, Allen-Hoffmann BL, Mosher DF. Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes. Detection and identification of transglutaminase gene products based on reverse transcription-polymerase chain reaction with degenerate primers. J Biol Chem 1998; 273:3452-60.
13. Upchurch HF, Conway E, Patterson MK Jr, Maxwell MD. Localization of cellular transglutaminase on the extracellular matrix after wounding: characteristics of the matrix bound enzyme. J Cell Physiol 1991; 149:375-82.
14. Buxman MM, Kocarnik MJ, Holbrook KA. Differentiation markers in fetal epidermis: transglutaminase and transpeptidase. J Invest Dermatol 1979; 72:171-7.
15. Watt FM. Involucrin and other markers of keratinocyte terminal differentiation. J Invest Dermatol 1983; 81:100s-3s.
16. Peterson LL, Wuepper KD. Epidermal and hair follicle transglutaminases and crosslinking in skin. Mol Cell Biochem 1984; 58:99-111.
17. Obinata A, Endo H. Induction of chick epidermal transglutaminase by hydrocortisone in ovo and in vitro with reference to the differentiation of epidermal cells. J Biol Chem 1979; 254:8487-90.
18. Steinert PM, Idler WW. Postsynthetic modifications of mammalian epidermal alpha-keratin. Biochemistry 1979; 18:5664-9.
19. Rice RH, Green H. Relation of protein synthesis and transglutaminase activity to formation of the cross-linked envelope during terminal differentiation of the cultured human epidermal keratinocyte. J Cell Biol 1978; 76:705-11.
20. Choi Y, Fuchs E. TGF-beta and retinoic acid: regulators of growth and modifiers of differentiation in human epidermal cells. Cell Regul 1990; 1:791-809.
21. Aeschlimann D, Paulsson M. Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71:402-15.
22. Kim SY, Chung SI, Steinert PM. Highly active soluble processed forms of the transglutaminase 1 enzyme in epidermal keratinocytes. J Biol Chem 1995; 270:18026-35.
23. Thacher SM, Rice RH. Keratinocyte-specific transglutaminase of cultured human epidermal cells: relation to cross-linked envelope formation and terminal differentiation. Cell 1985; 40:685-95.
24. Ghosh MM, Boyce S, Layton C et al. A comparison of methodologies for the preparation of human epidermal-dermal composites. Ann Plast Surg 1997; 39:390-404.
25. Chakrabarty KH, Dawson RA, Harris P et al. Development of autologous human dermal-epidermal composites based on sterilized human allodermis for clinical use. Br J Dermatol 1999; 141:811-23.
26. Sahota PS, Burn JL, Heaton M et al. Development of a reconstructed human skin model for angiogenesis. Wound Repair Regen 2003; 11:275-84.
27. Ralston DR, Layton C, Dalley AJ et al. Keratinocytes contract human dermal extracellular matrix and reduce soluble fibronectin production by fibroblasts in a skin composite model. Br J Plast Surg 1997; 50:408-15.
28. Chakrabarty KH, Heaton M, Dalley AJ et al. Keratinocyte-driven contraction of reconstructed human skin. Wound Repair Regen 2001; 9:95-106.
29. Harrison CA, Heaton MJ, Layton CM, MacNeil S. Use of an in vitro model of tissue-engineered human skin to study keratinocyte attachment and migration in the process of reepithelialization. Wound Repair Regen 2006; 14:204-10.
30. Freund KF, Doshi KP, Gaul SL et al. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994; 33:10109-19.
31. Skill NJ, Johnson TS, Coutts IG et al. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 2004; 279:47754-62.
32. Griffin M, Coutts IG, Saint RE. Novel compounds and methods of using the same. GB Patent 2004/002569. Issued 29 December 2004.
33. Lorand L, Campbell-Wilkes LK, Cooperstein L. A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem 1972; 50:623-31.
34. Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: a possible sign of Netherton syndrome. Pediatr Dermatol 1996; 13:183-99.
35. Huber M, Rettler I, Bernasconi K et al. Lamellar ichthyosis is genetically heterogeneous: cases with normal keratinocyte transglutaminase. J Invest Dermatol 1995; 105:653-4.
36. Shevchenko YO, Compton JG, Toro JR et al. Splice-site mutation in TGM1 in congenital recessive ichthyosis in American families: molecular, genetic, genealogic, and clinical studies. Hum Genet 2000; 106:492-9.
37. Traupe H, Kolde G, Happle R. Autosomal dominant lamellar ichthyosis: a new skin disorder. Clin Genet 1984; 26:457-61.
38. Williams ML, Elias PM. Heterogeneity in autosomal recessive ichthyosis. Clinical and biochemical differentiation of lamellar ichthyosis and nonbullous congenital ichthyosiform erythroderma. Arch Dermatol 1985; 121:477-88.
39. Williams ML. Ichthyosis: mechanisms of disease. Pediatr Dermatol 1992; 9:365-8.
40. Williams ML, Elias PM. From basket weave to barrier. Unifying concepts for the pathogenesis of the disorders of cornification. Arch Dermatol 1993; 129:626-9.
41. Tavadia S, Mortimer E, Munro CS. Genetic epidemiology of Darier's disease: a population study in the west of Scotland. Br J Dermatol 2002; 146:107-9.
42. Burge SM, Garrod DR. An immunohistological study of desmosomes in Darier's disease and Hailey-Hailey disease. Br J Dermatol 1991; 124:242-51.
43. Ikeda S, Mayuzumi N, Shigihara T et al. Mutations in ATP2A2 in patients with Darier's disease. J Invest Dermatol 2003; 121:475-7.
44. Racz E, Csikos M, Benko R et al. Three novel mutations in the ATP2A2 gene in Hungarian families with Darier's disease, including a novel splice site generating intronic nucleotide change. J Dermatol Sci 2005; 38:231-4.
45. Krueger G, Ellis CN. Psoriasis: recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53:S94-100.
46. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455:221-5.
47. Abel EA, DiCicco LM, Orenberg EK et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15:1007-22.
48. Wolf R, Lo SA, Lombardi ML et al. The in vitro effect of hydroxychloroquine on skin morphology and transglutaminase. Int J Dermatol 1997; 36:704-7.
49. Sjolin-Forsberg G, Berne B, Johansson M et al. Differential uptake of chloroquine by human keratinocytes and melanocytes in culture. Arch Dermatol Res 1996; 288:211-15.
50. Ruocco V, De Angelis E, Lombardi ML. Drug-induced pemphigus. II. Pathomechanisms and experimental investigations. Clin Dermatol 1993; 11:507-13.
51. Esposito C, Ruocco V, Cozzolino A et al. Are acantholysis and transglutaminase inhibition related phenomena? Dermatology 1996; 193:221-5.
52. Takahashi H, Isobe T, Horibe S et al. Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1. J Biol Chem 2000; 275:23589-95.
53. Akimov SS, Krylov D, Fleischman LF, Belkin AM. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 2000; 148:825-38.
54. Isobe T, Takahashi H, Ueki S et al. Activity-independent cell adhesion to tissue-type transglutaminase is mediated by alpha4beta1 integrin. Eur J Cell Biol 1999; 78:876-83.
55. Gaudry CA, Verderio E, Jones RA et al. Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the beta(1) integrin. Exp Cell Res 1999; 252:104-13.
56. Mils V, Basset-Seguin N, Moles JP et al. Comparative analysis of normal and psoriatic skin both in vivo and in vitro. Differentiation 1994; 58:77-86.
57. Barker CL, McHale MT, Gillies AK et al. The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 2004; 123:892-901.
58. Boelsma E, Gibbs S, Faller C, Ponec M. Characterization and comparison of reconstructed skin models: morphological and immunohistochemical evaluation. Acta Derm Venereol 2000; 80:82-8.
59. El Ghalbzouri A, Gibbs S, Lamme E et al. Effect of fibroblasts on epidermal regeneration. Br J Dermatol 2002; 147:230-43.
60. Asselineau D, Bernhard B, Bailly C, Darmon M. Epidermal morphogenesis and induction of the 67 kD keratin polypeptide by culture of human keratinocytes at the liquid-air interface. Exp Cell Res 1985; 159:536-9.